In the case of AML, bevacizumab was proposed to inhibit leukemia cells by two proposed mechanisms: first, when considering that AML myeloblasts can express VEGF isoforms and VEGFR2, anti-VEGF therapies may have a direct inhibitory effect on malignant myeloblasts. Here, VEGFA is linked to leukemia.